For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Non-alcoholic steatohepatitis (NASH), is one of the common liver diseases, often called silent liver disease. The major feature in NASH is fat deposition in the liver, along with inflammation.
Scope of the Report:
This report studies the Nonalcoholic Steatohepatitis (NASH) market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Nonalcoholic Steatohepatitis (NASH) market by product type and applications/end industries.
NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.
At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy.
Asia-Pacific presents lucrative opportunities for the key players operating in the non-alcoholic steatohepatitis (NASH) market. Some factors such as growth in diagnostic techniques, rapid rise in prevalence NASH, growth in economies, and increase in demand for NASH therapeutics drive the market growth in Asia-Pacific.
The global Nonalcoholic Steatohepatitis (NASH) market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Nonalcoholic Steatohepatitis (NASH).
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
- Tobira Therapeutics
- Cadila Healthcare
- Conatus Pharmaceuticals
- Galmed Pharmaceuticals
- Gemphire Therapeutics
- Gilead Sciences
- Intercept Pharmaceuticals
- Novartis International
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Vitamin E & Pioglitazone
- Selonsertib & Cenicriviroc
Market Segment by Applications, can be divided into
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy